48079-8 |
3,6-Epoxydodecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3,6-Epoxydodecanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48079-8 |
|
|
|
|
Both |
|
|
|
0 |
3,6-epoxydodecanedioate/Creat Ur-sRto |
|
|
|
N |
|
3,6-epoxydodecanedioic acid; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
4808-2 |
HLA-B14 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B14 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4808-2 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B14 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48080-6 |
3,6-Epoxyoctanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3,6-Epoxyoctanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48080-6 |
|
|
|
|
Both |
|
|
|
0 |
3,6-epoxyoctanedioate/Creat Ur-sRto |
|
|
|
N |
|
3,6-epoxyoctanedioic acid; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48081-4 |
3,6-Epoxytetradecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3,6-Epoxytetradecanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48081-4 |
|
|
|
|
Both |
|
|
|
0 |
3,6-epoxytetradecanedioate/Creat Ur-sRto |
|
|
|
N |
|
3,6-epoxytetradecanedioic acid; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48082-2 |
3-Hydroxyadipate 3,6-lactone/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxyadipate 3,6-lactone/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48082-2 |
|
|
|
|
Both |
|
|
|
0 |
3OH-adipate 3,6-lactone/Creat Ur-sRto |
|
|
|
N |
|
3-hydroxy-adipate; 3-hydroxyadipic acid; 3-Hydroxyadipolactone; 3OH-Adipate; 3OH-adipate 3,6-lactone; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48083-0 |
3-Hydroxydodecanedienedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxydodecanedienedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48083-0 |
|
|
|
|
Both |
|
|
|
0 |
3OH-dodecanedienedioate/Creat Ur-sRto |
|
|
|
N |
|
3-Hydroxy dodecanedienedioate; 3-hydroxydodecanedienedioic acid; 3OH-dodecanedienedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48084-8 |
3-Hydroxydodecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxydodecanedioate (3-OH-D-C12)/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48084-8 |
|
|
|
|
Both |
|
|
|
0 |
3OH-dodecanedioate/Creat Ur-sRto |
|
|
|
N |
|
3-Hydroxy dodecanedioate; 3-hydroxydodecedioic acid; 3OH-dodecanedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48085-5 |
3-Hydroxydodecenedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxydodecenedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48085-5 |
|
|
|
|
Both |
|
|
|
0 |
3OH-dodecenedioate/Creat Ur-sRto |
|
|
|
N |
|
3-Hydroxy dodecenedioate; 3-hydroxydodecenedioic acid; 3OH-dodecenedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48086-3 |
3-Hydroxytetradecadienedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxytetradecadienedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48086-3 |
|
|
|
|
Both |
|
|
|
0 |
3OH-Tdecadienedioate/Creat Ur-sRto |
|
|
|
N |
|
3-hydroxytetradecadienedioic acid; 3OH-Tdecadienedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48087-1 |
3-Hydroxytetradecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxytetradecanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48087-1 |
|
|
|
|
Both |
|
|
|
0 |
3OH-Tdecanedioate/Creat Ur-sRto |
|
|
|
N |
|
3-Hydroxy tetradecanedioate; 3-hydroxytetradecanedioic acid; 3OH-Tdecanedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48088-9 |
3-Hydroxytetradecenedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3-Hydroxytetradecenedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48088-9 |
|
|
|
|
Both |
|
|
|
0 |
3OH-Tdecenedioate/Creat Ur-sRto |
|
|
|
N |
|
3-Hydroxy tetradecenedioate; 3-hydroxytetradecenedioic acid; 3OH-Tdecenedioate; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48089-7 |
Cholesterol/Apolipoprotein B |
SRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol/Apolipoprotein B [Molar ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
48089-7 |
|
|
|
|
Observation |
|
|
|
0 |
Cholest/Apo B SerPl-sRto |
|
|
|
N |
|
APO; Apo B; ApoB; Apolipo; Apolipoprot; Apolipoproteins; Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Lipid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration ratio; Substance ratio |
2.42 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4809-0 |
HLA-B14 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B14 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4809-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B14 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48090-5 |
Cholesterol.in HDL/Cholesterol.in HDL+Cholesterol.in VLDL |
SRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in HDL/Cholesterol in HDL+VLDL [Molar ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
48090-5 |
|
|
|
|
Observation |
|
|
|
0 |
HDLc/HDLc+VLDLc SerPl-sRto |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; HDLc; HDL-C; HDLc+VLDLc; Heart Disease; High density lipoprotein cholesterols; Lipid; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration ratio; Substance ratio; TCHHDL; Very low density lipoprotein cholesterols; VLDLc |
2.42 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
48091-3 |
Corticotropin^12 AM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --12 AM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48091-3 |
|
|
|
|
Both |
|
|
|
0 |
ACTH 12 AM Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; Midnight; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48092-1 |
Corticotropin^12 PM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --12 PM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48092-1 |
|
|
|
|
Both |
|
|
|
0 |
ACTH 12 PM Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Evening; Level; Mass concentration; Noon; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48093-9 |
Corticotropin^15M pre 1 ug/kg CRH IV |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --15 minutes pre 1 ug/kg CRH IV |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48093-9 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 15M pre 1 ug/kg CRH IV Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; Before; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; i; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48094-7 |
Corticotropin^4 AM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --4 AM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48094-7 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 4 AM specimen Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; Morning; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48095-4 |
Corticotropin^4 PM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --4 PM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48095-4 |
|
|
|
|
Both |
|
|
|
0 |
ACTH 4 PM Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Evening; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48096-2 |
Corticotropin^8 AM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --8 AM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48096-2 |
|
|
|
|
Observation |
|
|
|
0 |
ACTH 8 AM Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; Morning; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48097-0 |
Corticotropin^8 PM specimen |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Corticotropin [Mass/volume] in Plasma --8 PM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ng/L |
|
|
|
|
|
|
CHAL |
|
48097-0 |
|
|
|
|
Both |
|
|
|
0 |
ACTH 8 PM Plas-mCnc |
|
|
|
N |
|
ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Evening; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rc206; Spec; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
48098-8 |
Cortisol^12 AM specimen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --12 AM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
|
|
|
|
|
|
CHAL |
|
48098-8 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 12 AM SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; Level; Mass concentration; Midnight; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
48099-6 |
Cortisol^12 PM specimen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --12 PM specimen |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
|
|
|
|
|
|
CHAL |
|
48099-6 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 12 PM SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Evening; F; hydrocortisone; Level; Mass concentration; Noon; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
481-2 |
Talampicillin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Talampicillin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
481-2 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Talampicillin Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; Fisiopen; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Talpen; Ticillina |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4810-8 |
HLA-B15 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B15 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4810-8 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B15 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |